Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma ; day:10 ; month:8 ; year:2024 ; pages:1-17
Oncology and Therapy ; (10.8.2024), 1-17
- Creator
-
Du, Ella Xiaoyan
Betts, Keith A.
Wang, Travis
Kitchen, Sophie A.
He, Xuanhao
Yin, Xin
Guttenplan, Sarah B.
Beauchamp, Karen
Delgado, Andrew
Rosenblatt, Lisa
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-024-00297-0
- URN
-
urn:nbn:de:101:1-2410292105111.016663185544
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Du, Ella Xiaoyan
- Betts, Keith A.
- Wang, Travis
- Kitchen, Sophie A.
- He, Xuanhao
- Yin, Xin
- Guttenplan, Sarah B.
- Beauchamp, Karen
- Delgado, Andrew
- Rosenblatt, Lisa
- SpringerLink (Online service)
Other Objects (12)
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Nivolumab plus Ipilimumab - Kombinationsansatz ermöglicht Chance auf Langzeitüberleben : entitätsübergreifender Einsatz der dualen Immuntherapie
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Nivolumab plus Ipilimumab - Kombinationsansatz ermöglicht Chance auf Langzeitüberleben : entitätsübergreifender Einsatz der dualen Immuntherapie
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Nivolumab plus Ipilimumab - Kombinationsansatz ermöglicht Chance auf Langzeitüberleben : entitätsübergreifender Einsatz der dualen Immuntherapie